

Studien / Forschung Lungenkrebszentrum

NSCLC

- Studie A Phase II, randomized Study : Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (**ALK+ NSCLC**) patients.
Rekrutierung: **offen** **ABP**
- Studie A Phase III, randomized, Placebo-controlled, double-blind, multicenter, International Study of Durvalumab with stereotactic Body Radiation Therapy (SBRT) for the treatment of patients with **unresected Stage I/II, lymph-node negative** Non-small Cell lung cancer. - Main cohort and Osimertinib cohort
Rekrutierung: **offen** **Pacific 4**
- Studie A Phase II, open-Label, multi-centre, International Safety Study of Durvalumab following sequential chemotherapy and radiation therapy in patients with **Stage III, unresectable** Non-small Cell Lung Cancer.
Rekrutierung: **geschlossen** Studie : **offen** **Pacific6**
- Studie A Phase III, randomized, double-blind, Placebo-controlled, multicenter Study comparing Niraparib plus Pembrolizumab versus Placebo plus Pembrolizumab as maintenance therapy in participants whose disease has remained stable or responded to first-line Platinum-based chemotherapy with Pemprolizumab for **Stage IIIB/IIIC or IV** Non-Small Cell Lung Cancer.
Rekrutierung: **offen** **Zeal -1**

Register für NSCLC und SCLC

- Register Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients **CRISP**
NSCLC BSC / Stadium I-III / Stadium IV
Rekrutierung: **offen (alle 3 Arme)**
SCLC BSC / Stadium I-III / Stadium IV
Rekrutierung: **pausiert (alle 3 Arme)**

In Vorbereitung:

NSCLC

- Studie *A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, INTERNATIONAL STUDY TO DETERMINE THE EFFICACY OF DURVALUMAB PLUS OLECLUMAB AND DURVALUMAB PLUS MONALIZUMAB IN PARTICIPANTS **WITH LOCALLY ADVANCED (STAGE III), UNRESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE NOT PROGRESSED FOLLOWING DEFINITIVE, PLATINUM-BASED CONCURRENT CHEMORADIATION THERAPY.*** **Pacific 9**
- Studie *A PHASE II STUDY OF BA3011 ALONE AND IN COMBINATION WITH NIVOLUMAB IN **ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHO HAD PRIOR DISEASE PROGRESSION ON A PD-1/L1, EGFR, OR ALK INHIBITOR .*** **BA3011**
- Studie *A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF BA3021 ALONE AND IN COMBINATION WITH NIVOLUMAB IN **PATIENTS WITH ADVANCED SOLID TUMORS.*** **BA3021**

SCLC

- Studie *A PHASE III , RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH ATEZOLIZUMAB AS MAINTENANCE THERAPY IN **PARTICIPANTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER(ES-SCLC) FOLLOWING FIRST-LINE INDUCTION THERAPY WITH CARBOPLATIN, ETOPOSIDE AND ATEZOLIZUMAB.*** **IMforte**

Mai 22

PI Dr. med. Monika Heilmann		
Ansprechpartner*innen:		
Dr. med Mariët van't Klooster	- Studienärztin (0511 927 2543)	mariet.vant.klooster@krh.de
Nadja Schachteli	- Study Nurse (0511 927 1913)	nadja.schachteli@krh.de
Manuela Willscher	- Study Nurse (0511 927 1914)	manuela.willscher@krh.de
FAX: 0511 927 97 7080		

KRH, Klinikum Siloah, Lungenkrebszentrum